Tiziana Life Sciences rises on advancing diabetes treatment program

Tiziana Life Sciences

18/04/2023 14:24

** Drug developer Tiziana Life Sciences Ltd's  TLSA.O 
shares rise 6.7% to $1.26 premarket
    ** Company says it is initiating a program to develop its
lead drug candidate, foralumab, for treatment or prevention of
type 1 diabetes
    ** Foralumab, is an antibody-based drug which targets
receptors called CD3 on the surface of immune
response-generating T cells and produces anti-inflammatory
effects - TLSA
    ** Company says CD3 has emerged as an "established and
attractive" target for type 1 diabetes after $2.9 billion
acquisition of Provention Bio by Sanofi
    ** As of last close, TLSA shares nearly doubled so far this
year

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com))